

Review Article

Vitamin D and extra-skeletal health: causality or consequence

Omar M. Al Nozha

Abstract

Vitamin D deficiency /insufficiency is widely recognized as a global health problem that is likely to be involved in pathogenesis or progression of many acute and chronic health disorders. Its relation to skeletal health has been clearly demonstrated and thoroughly examined. This review aims to highlight the continuous debate about the relation between vitamin D and extra-skeletal health and whether it is a causality or just an association. Overall, the available evidence does not meet the criteria for establishing cause-and-effect relationships because of the limitations of observational studies to corroborate the causality due to many potential confounders. Moreover, the causal relationship couldn't be established in randomized studies or in many meta-analyses. This may reflect the fact that vitamin D level reduction is just a biomarker of ill health. The inflammatory processes involved in the disease occurrence and the functional limitations of the diseases would have a role in reducing serum 25-hydroxy vitamin D "25 (OH) D" level, which would explain why low vitamin D is reported in a wide range of disorders. This may underscore the possibility of harm instead of benefit of vitamin D supplementation when its exact role is not fully established, thus many guidelines and interest groups are still hesitant toward recommending replacement in extra-skeletal disease. Future directions entails the need for a large well-designed randomized control trials (RCTs) to resolve the active debate on the benefits of vitamin D replacement for extra-skeletal disease, and not only that, future studies should establish specific, clinically relevant effects of vitamin D repletion, provide cut-values for optimal serum levels of 25 (OH) D, and appropriate doses for non-skeletal health benefits.

Key words: Vitamin D; Diabetes; Cancer; immune system; cardiovascular disease

Correspondence:

Omar M. Al Nozha (MD)

Assistant Professor of Medicine & Consultant Endocrinologist

College of Medicine, Taibah University,

Madinah, Kingdom of Saudi Arabia

Head; Saudi Society of Endocrinology & Metabolism (SSEM) - Madinah Chapter

P. O. Box: 30088, P.C. 41477

Mobile: 0555344992

Fax: 014-8484800

Personal Email: alnozha@hotmail.com

Official Email: ozoghaibi@taibahu.edu.sa

Introduction

The discovery of the potential non-skeletal functions of vitamin D has received tremendous amount of attention with increasing reports of association between vitamin D deficiency and a wide range of health conditions. Over the last decades, the defined genome-wide map of vitamin D receptor (VDR) binding was recognized to potentially regulate the pleiotropic effects of the active metabolite to 1,25-dihydroxy vitamin D $3(1,25-(OH)_2D_3)$.⁽¹⁾ The VDR and the alpha-hydroxylase enzyme are the key factors in the non-skeletal functions of the VDR-vitamin D endocrine system. Many tissues express the 1-alpha-hydroxylase enzyme including the skin, gastro intestinal tract, vessels, mammary epithelial cells, osteoblasts, osteoclasts and granulomatous tissues, and therefore can generate the active form in an auto or paracrine way.⁽²⁾ The active form then binds to the VDR which is expressed in nearly all nucleated cells, then vitamin D with its VDR form a hetero dimer with retinoid X receptor which binds to genomic sequences (vitamin D response elements) to regulate gene expression.⁽¹⁾ Many reviews has explored the relationship between vitamin D and extra-skeletal health.⁽³⁻⁵⁾ The objective of this review is neither to examine in depth all the available evidence exploring the relationship between vitamin D and extra-skeletal health, nor to look into the breakthroughs and molecular advances in vitamin D in relation to this subject. Rather it aims to highlight the results or conclusions of conflicting major trials that have explored this relationship to contribute further in this active debate of causality vs. consequence. It is more likely to end up with more questions in mind rather than finding answers by the end of the review.

Search Strategy

The review had intentionally focused on major RCTs that had conflicting conclusions to serve the aim of the intended debate. The literature review was conducted on PubMed, Google scholar and science direct search engine using the following search key words:

(Vitamin D, Diabetes, Cancer, immune system and cardiovascular disease). And some search filters were applied on and off such as (systematic review, meta-analysis, randomized control trials, observational study)

with special focus on human studies and papers published in English.

Immune Mediated Diseases

The field of vitamin D immunology has revolutionized long time back by the findings that monocytes, macrophages, dendritic cells and activated T and B cells express the specific high-affinity VDR and 1 α -hydroxylase activities.⁽⁶⁾ Existing animal and human data indicate that 1,25-(OH) $_2D_3$ could modulate immune system in the direction of immune regulation and anti-inflammation through inhibition of the acquired autoimmunity, this has been thoroughly reviewed by Ponsonby et. al.⁽⁷⁾ and through activation of the innate immune system.⁽⁸⁾ The mechanism of action of vitamin D on mycobacterium tuberculosis (TB) infection for example, became clearer when scientists reported the effect of activation of toll-like receptors (TLR) of the macrophages by innate immune response, in humans infected with TB, on the up-regulation of VDR expression.⁽⁹⁾ Activation of these receptors also leads to generation of intra cellular active form of vitamin D and eventually leading to the production of an antimicrobial peptides such as "Cathelicidin."^(9,10) Both cathelicidin and β -defensin play a major role in the immune defense especially in respiratory tract infection via inactivating viral pathogens⁽¹¹⁾ as well as recruiting phagocytes.⁽¹²⁾ VDR polymorphism is common and could be associated with defects in gene activation which can explain the increasing risk for developing auto immune diseases in some patients.⁽¹³⁾ However, little research addressed the relevance of VDR gene polymorphism to immune regulation or auto immune disease.⁽¹⁴⁾ Pre-treatment with 1,25-(OH) $_2D_3$ in animal models inhibits the progression of most common auto immune diseases, including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease.⁽¹⁵⁻¹⁷⁾ The efficacy and/ or safety of vitamin D supplementation in preventing auto immune disease in human are not well studied with few clinical trials suggesting a beneficial effects.⁽¹⁸⁾ However, there is growing possibility that persistent bacteria drive chronic autoimmune/ inflammatory diseases and the use of vitamin D (asecosteroid) may improves symptoms, but allows chronic pathogens to proliferate over time.⁽⁶⁾

Infectious Diseases

Epidemiologic studies have demonstrated a strong association between seasonal variations in vitamin D concentrations and seasonal epidemic outbreaks, morbidity and mortality of viral infections.⁽²⁰⁾ Trial of vitamin D supplementation in infection revealed conflicting results ranging from lower risk in children with severe vitamin D deficiency in one RCT⁽²¹⁾ to no role in reducing the incidence of upper respiratory infections in other RCTs.^(22, 23) One systemic review of 13 RCTs found mixed results, with some trials reported that adequate vitamin D concentrations may decrease all-cause infection rates.⁽²⁴⁾ However, the beneficial clinical effects of vitamin D; as supplementary treatment in patients with tuberculosis, was not detected in RCTs.^(25, 26) And a systematic review concluded that there is no sufficient evidence to recommend any nutritional supplements for treating patients with active tuberculosis.⁽²⁷⁾

Cell proliferation and Cancer

Vitamin D inhibits cellular proliferation and angiogenesis, reduces inflammation, promotes differentiation and apoptosis.⁽²⁸⁾ An extensive review of the relationship of vitamin D and cancer concluded that living at a high latitude may expose people to cancer, associating this with ultraviolet B exposure and vitamin D synthesis.⁽²⁹⁾ Initial human studies reported a possible association between vitamin D status and the risk of almost all cancer types with the greatest risk in association with colon cancer.⁽²⁸⁾ In a nested case-control study; in 2496 European participants, a higher incidence rate ratio of colon cancer (1.28) was reported in participants with serum 25(OH)D levels between 10 and 20 ng/mL (25 to 50 nmol/L) compared with those with 20 to 30 ng/mL (50 to 75 nmol/L) serum levels.⁽³⁰⁾ One recent study found an inverse association between colorectal cancer and higher versus lower vitamin D level (OR, 0.60, 95% CI; 0.38–0.94) but not with the vitamin binding protein.⁽³¹⁾ In a meta-analysis of 9 case-control studies, a 6% (95% CI; 3-9 %) reduction in the risk of colon cancer for each 4 ng/mL (10 nmol/L) increase in basal serum 25 (OH) D concentration was detected.⁽³²⁾ For prostate cancer, 3 meta-analyses of prospective studies found no relationship with circulating 25 (OH) D,⁽³³⁻³⁵⁾

but on the contrary, a significantly increased risk was reported in men with higher serum 25 (OH) D concentrations.⁽³⁶⁾ For pancreatic cancer, higher vitamin D concentrations (>100nmol/L) were associated with a 3-fold increased risk (OR,2.92, 95% CI; 1.56-5.48) in one study⁽³⁷⁾ this association has been explored further in the overview of the cohort consortium of Vitamin D Pooling Project of Rarer Cancers (VDPP) which had similar conclusion.⁽³⁸⁾

In a meta-analysis of prospective studies, the risk of post-menopausal breast cancer decreased with 25 (OH) D levels between 27 and <35ng/mL (67to<87nmol/L), with no further reduction for levels above 35ng/mL.⁽³⁹⁾ The same meta-analysis also reported a significant inverse association between vitamin D level and the risk of post-menopausal breast cancer but not pre-menopausal cancer.⁽³⁹⁾

Unfortunately, the results of RCTs on *protective effect of vitamin D* on cancer risk are inconsistent. One small clinical trial of vitamin D and calcium supplementation found more than 60% reduced overall risk of all cancers in post-menopausal women who received calcium with and without vitamin D.⁽⁴⁰⁾ However, in the famous Women's Health Initiative trial, there was no effect on the incidence of colorectal cancer using vitamin D3 (400units/day) and calcium (1000mg/day).⁽⁴¹⁾ In a comprehensive review and meta-analysis of twenty papers examining vitamin D blood levels or the dietary intake of vitamin D in relation to skin cancer (melanoma and none melanoma skin cancer) has concluded that vitamin D intake (diet and/or supplements) doesn't seem to have any protective effect against the development of skin cancer.⁽⁴²⁾

Hypertension

The geographic and racial variation in blood pressure (BP) could be partly explained by the exposure to sunlight and subsequent vitamin D synthesis.⁽⁴³⁾ Animal studies showed that the active form of vitamin D takes parts in regulation of the renin-angiotensin system with a resultant anti-hypertensive and vascular protective effects.⁽⁴⁴⁾ Mice with in born deficiency of the 1-alpha-hydroxylase gene develop high renin hypertension and cardiac hypertrophy.⁽⁴⁴⁾ Epidemiological studies suggested that vitamin D deficiency may be an independent risk factor for arterial

hypertension. In the Third National Health and Nutrition Examination Survey (NHANESIII) the mean systolic BP was about 3 mm Hg lower in those with the highest quintile of serum 25 (OH) D levels in comparison with those in the lowest quintile. ⁽⁴⁵⁾ Another meta-analysis of 18 studies reported a pooled odds ratio (OR) of hypertension of 1.37 (95% CI; 1.19 – 1.59) for the lowest versus the highest vitamin D levels. ⁽⁴⁶⁾ In a meta-analysis of 11 RCTs, a significant reduction in diastolic BP of –3.1 mm Hg (–5.5 – –0.6) with vitamin D therapy was found only in hypertensive patients. ⁽⁴⁷⁾ Another meta-analysis ⁽⁴⁸⁾ of 4 RCTs found that vitamin D administration reduced systolic BP by 2.44mm Hg (–4.86–0.02) irrespective to the dose, duration, or intervention. However, in another meta-analysis of 10 trials reported no significant overall effect of vitamin D supplementation on BP except in trials using higher doses of vitamin D (>1000 IU per day) where a significant lowering of diastolic BP was reported (–1.5 mm Hg). ⁽⁴⁹⁾

Cardiovascular Disease (CVD) and Cardiovascular Mortality

Observational studies found that the prevalence of vitamin D deficiency, CVD, diabetes, and hypertension increases with increasing distance from the equator and suggested a role of ultra violet light exposure and vitamin D synthesis in the geographic and racial differences. ⁽⁴³⁾ Data analysis from the NHANES III revealed an inverse relation between serum levels of 25 (OH) D and major cardiovascular risk factors including hypertension, diabetes mellitus, hypertriglyceridemia, and obesity in 15,088 subjects from United States with increased OR for cardiovascular events (1.24), heart failure (2.10), and peripheral arterial diseases (1.82) in adults with 25 (OH) D levels <20 ng/mL. ⁽⁵⁰⁾ The Framingham offspring study followed 1,739 participants for a mean of 5.4 years and found 53% to 80% higher rates of a composite CV end point (fatal or nonfatal MI, ischemia, stroke, or heart failure) in people with low vitamin D levels with 1.62 hazard ratio of the first cardiovascular event in persons with 25 (OH) D value below 15 ng/mL than those with higher values. ⁽⁵¹⁾ In a large meta-analysis which included 19 prospective studies with 65,994 participants reported a relative risk (RR) of CVD of 1.03 (95% CI; 1.00-1.60) per

10 ng/mL (25 nmol/L) decrement in serum 25 (OH) D). ⁽⁵²⁾ In a meta-analysis of good quality studies the RR of increased CV events associated with hypovitaminosis D was 1.27 (95% CI; 1.04-1.56). ⁽⁵³⁾ The reported beneficial actions of vitamin D on CVD include modulation of classic cardio vascular risk factors, ^(50, 54) and modulation of endothelial dysfunction. ⁽⁵⁴⁾ Moreover, secondary hyperparathyroidism in patients with chronic low vitamin D is associated with increased risk of CVD and mortality. ⁽⁵⁵⁾ A meta-analysis of prospective studies found an inverse association with cardiovascular events and mortality. ⁽⁵⁶⁾ Deficient or insufficient serum 25 (OH) D levels have been documented also to predict heart failure, ⁽⁵⁷⁾ peripheral arterial disease, ⁽⁵⁸⁾ stroke, ⁽⁵⁹⁾ and cardio vascular mortality. ⁽⁵⁸⁾ Unfortunately, the results of vitamin D supplementation and the incidence of vascular diseases are not encouraging. In an extensive meta-analysis of 51 RCTs, vitamin D supplementation showed no significant effects on death (RR 0.96), myocardial infarction (RR 1.02), or stroke (RR 1.05). ⁽⁶⁰⁾ In another systematic review of vitamin D and cardio metabolic outcomes, 4 trials found no effect of supplementation on cardiovascular outcomes. ⁽⁵⁴⁾

Diabetes Mellitus (DM)

While it's not well understood how vitamin D acts on glucose homeostasis, postulated mechanisms include immune modulation, anti-inflammation, insulin synthesis and secretion, and insulin sensitivity. ⁽⁶¹⁾ Moreover, VDR gene polymorphisms may influence pancreatic secretion of insulin and glucagon with development of type 1 DM in some populations, and a link between low vitamin D and type 1 DM has been suggested in some observational studies. ⁽⁶²⁾ However, a 13-year nationwide Danish study found no difference in Vitamin D levels between children newly diagnosed with type 1 diabetes and their healthy siblings. ⁽⁶³⁾ Another interesting study found that severe vitamin D deficiency is an independent predictor of all-cause mortality but not retinopathy or nephropathy in patients with type 1 DM. ⁽⁶⁴⁾ On the other hand one birth-cohort study of 10,366 Finnish children found a significantly reduced risk of 0.22 for type 1 DM with high-dose vitamin D supplementation. ⁽⁶⁵⁾ A European Community Concerted Action

Program in Diabetes subgroup multicentre study found a significantly reduced risk for type 1 DM in countries with vitamin D supplementation. ⁽⁶⁶⁾ These results are supported by a meta-analysis of 5 studies. ⁽⁶⁷⁾ However, still there is no enough evidence to support vitamin D supplementation to prevent diabetes type one in susceptible children. On the other hand, many studies have linked low vitamin D status with the development of metabolic syndrome ⁽⁶⁸⁾ and diabetes type 2. ⁽⁶⁹⁻⁷¹⁾ The postulated mechanisms are not completely clarified including VDR-mediated insulin synthesis and secretion ⁽⁶²⁾ and vitamin D₂₅-regulation of lipoprotein lipase enzyme. ⁽⁶⁹⁾ In a meta-analysis of prospective studies; low vitamin D concentrations have been associated with an increased risk of development of type 2 DM in the general population. ⁽⁷⁰⁾ In another meta-analysis of 21 prospective studies, the summary RR for type 2 diabetes was 0.62 for patients with the highest versus lowest category of 25(OH) D values. ⁽⁷¹⁾ A meta-analysis showed that the highest prevalence of type 2 DM (0.36) was associated with the lowest blood levels of 25 (OH) D in non-black individuals and the prevalence of metabolic syndrome (0.71) was highest among those with the lowest dairy intake. ⁽⁷²⁾ Many trials addressed the prevention of incident type 2 diabetes by vitamin D supplementation. In the large Women's Health Initiative study, the combined use of vitamin D and calcium was found to lower the risk of incident type 2 DM. ⁽⁷³⁾ In the Nurses' Health Study, 83,779 women were followed for 20 years and found no association between total vitamin D intake and type 2 diabetes but when the highest and the lowest category of vitamin D intake were compared, the RR of type 2 diabetes was 0.87 (95% CI; 0.75-1.00). ⁽⁷⁴⁾ One systematic review of interventional trials of vitamin D found that prevention of incident type 2 DM by the combined use of vitamin D and calcium supplementation may occur only in patients with glucose intolerance. ⁽⁷²⁾ Interventional studies of vitamin D supplementation specifically designed for metabolic control of type 2 DM or diabetic complications are very few. One meta-analysis of 15 RCTs found that vitamin D supplementation did not exert any significant effect on fasting glucose, glycated hemoglobin or insulin resistance in diabetic patients. ⁽⁷⁵⁾

Similar results were obtained from another meta-analysis ⁽⁷⁶⁾ of 35 trials.

Conclusion and Future Directions

Consistently, observational studies have suggested an inverse association between low vitamin D concentrations and development of some extra-skeletal diseases. Some studies suggested that the association between serum 25 (OH) D levels and some illnesses as cancer, and mortality is a curvilinear indicating higher risk at both low and high serum levels. In contrast to observational studies, the results of RCTs using vitamin D supplementation in preventing or ameliorating these extra-skeletal diseases were disappointing. Results showed inconsistent reduction in the risk with supplementation even if the basal serum level was low and was raised to optimal levels. Some RCTs did not find a dose response relationship between serum 25 (OH) D and reported outcomes. Failure to show benefits of vitamin D supplementation on different health outcomes may be explained by possible methodology flaws like low power, inadequate supplementation, or insufficient follow-up, in addition to variability in basal vitamin D levels, dietary and sun exposure habits, and final 25 (OH) D levels between participants. Moreover, most RCTs have measured the 25 (OH) D levels with variable precision and did not ensure adequacy of supplementation by raising the 25 OHD levels to or above 30ng/ml. Most importantly, many published RCTs were performed in general populations (not vitamin D-deficient populations), not designed to primarily assess a vitamin D specific outcome variable, and with poorly defined treatment end points. One important confounding factor was the combined use of calcium supplementation, which can influence outcomes irrespective to vitamin D supplementation. Moreover, inter-individual variation in vitamin D status, host genes encoding vitamin D-responsive elements could affect the efficiency of vitamin D₃ supplementation as seen in studies of VDR polymorphisms.

Overall, the available evidence does not meet criteria for establishing cause-and-effect relationships because of the limitations of observational studies to corroborate the causality due to many potential confounders (age, smoking, diet, time of sun exposure, latitude, physical activity, body mass index,

vitamin D-binding protein). Theodoratou et al has summarized most of the available evidence derived from systematic reviews and meta-analyses in their review, ⁽⁷⁷⁾ it included 107 systematic reviews and 74 meta-analyses of observational studies and 87 meta-analyses of RCTs with 137 outcomes. It concluded that there is no strong evidence supporting vitamin D replacement efficacy in any outcome, but pointed that associations with a selection of outcomes are probable.

The discrepancy between observational and interventional studies should attract attention that vitamin D level in ill health can be just a biomarker of inflammation or ill health. The inflammatory processes involved in the disease occurrence and the functional limitations of the diseases would have a role in reducing the serum of 25 (OH) D bio availability, which would explain why low vitamin D status is reported in a wide range of disorders. Interestingly, the available data may underscore the hazard of supplementation when its exact role is not fully established in prevention or treatment of extra-skeletal diseases. Thus, unless more evidence of clinically meaningful effects of supplementation is available, it may be too early to recommend for or against vitamin D supplementation for maintenance of extra-skeletal health and prevention of disease, beyond the daily requirements for calcium homeostasis and skeletal benefits.

Future directions entails the need for large well-designed RCTs to solve the active debate on extra-skeletal effects of vitamin D supplementation, find specific and clinically relevant effects of vitamin D repletion, provide cut-values for optimal serum levels of 25 (OH) D, and appropriate doses for non-skeletal health benefits. A large ongoing trial, which is expected to find a bit more definitive answers, is the Australian D-Health study. The results of this study might clarify some of the current conflicting results and come out with more clear advice regarding replacement for extra-skeletal health.

References:

1. Ramagopalan, SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. *Genome research*. 2010; 20(10):1352-6-0.
2. Hewison M, Burke F, Evans KN, Lammas DA, Sansom DM, Liu P, et al. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. *J Steroid Biochem Mol Biol*. 2007; 103(3-5):316-21.
3. Bouvard B, Annweiler C, Salle A, Beauchet O, Chappard D, Audran M, et al. Extraskelletal effects of vitamin D: facts, uncertainties, and controversies. *Joint Bone Spine*. 2011; 78(1):10-6.
4. Holick MF. Vitamin D: extraskelletal health. *Endocrinol Metab Clin North Am*. 2010; 39(2):381-400, table of contents.
5. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. *Autoimmun Rev*. 2013; 12(10):976-89.
6. Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. *J Clin Endocrinol Metab*. 1983; 57(6):1308-10.
7. Ponsonby AL, McMichael A, van der Mei I. Ultraviolet radiation and autoimmune disease: insights from epidemiological research. *Toxicology*. 2002; 181-182:71-8.
8. Szodoray P, Nakken B, Gaal J, Jonsson R, Szegedi A, Zold E, et al. The complex role of vitamin D in autoimmune diseases. *Scand J Immunol*. 2008; 68(3):261-9.
9. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science*. 2006; 311(5768):1770-3.
10. Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, Skolimowska K, et al. IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. *J Immunol*. 2007; 178(11):7190-8.
11. Gropp R, Frye M, Wagner TOF, Bargon J. Epithelial Defensins Impair Adenoviral Infection: Implication for Adenovirus-

- Mediated Gene Therapy. *Human Gene Therapy*. 1999; 10(6):957-64.
12. Beisswenger C, Bals R. Antimicrobial Peptides in Lung Inflammation. *Chemical Immunology and Allergy: S. Karger AG*; 2005. p. 55-71.
 13. Tanaka A, Nezu S, Uegaki S, Kikuchi K, Shibuya A, Miyakawa H, et al. Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations. *Journal of Hepatology*. 2009; 50(6):1202-9.
 14. Smolders J, Peelen E, Thewissen M, Menheere P, Cohen Tervaert JW, Hupperts R, et al. The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. *Autoimmunity Reviews*. 2009; 8(7):621-6.
 15. Cantorna MT, Hayes CE, DeLuca HF. 1, 25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. *J Nutr*. 1998; 128(1):68-72.
 16. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. *Proceedings of the National Academy of Sciences*. 1996; 93(15):7861-4.
 17. Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1, 25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. *J Nutr*. 2000; 130(11):2648-52.
 18. M. Fletcher J, A. Basdeo S, C. Allen A, J. Dunne P. Therapeutic Use of Vitamin D and its Analogues in Autoimmunity. *Recent Patents on Inflammation & Allergy Drug Discovery*. 2012; 6(1):22-34.
 19. Albert PJ, Proal AD, Marshall TG. Vitamin D: The alternative hypothesis. *Autoimmunity Reviews*. 2009; 8(8):639-44.
 20. Grant WB. Variations in Vitamin D Production Could Possibly Explain the Seasonality of Childhood Respiratory Infections in Hawaii. *The Pediatric Infectious Disease Journal*. 2008; 27(9):853.
 21. Laaksi I, Ruohola JP, Mattila V, Auvinen A, Ylikomi T, Pihlajamäki H. Vitamin D Supplementation for the Prevention of Acute Respiratory Tract Infection: A Randomized, Double-Blinded Trial among Young Finnish Men. *The Journal of Infectious Diseases*. 2010; 202(5):809-14.
 22. Manaseki-Holland S, Maroof Z, Bruce J, Mughal MZ, Masher MI, Bhutta ZA, et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. *The Lancet*. 2012; 379(9824):1419-2.
 23. Ginde AA, Mansbach JM, Camargo CA. Association between Serum 25-Hydroxyvitamin D Level and Upper Respiratory Tract Infection in the Third National Health and Nutrition Examination Survey. *Arch Intern Med*. 2009; 169(4):384.
 24. Yamshchikov A, Desai N, Blumberg H, Ziegler T, Tangpricha V. Vitamin D for Treatment and Prevention of Infectious Diseases: A Systematic Review of Randomized Controlled Trials. *Endocrine Practice*. 2009; 15(5):438-49.
 25. Wejse C, Gomes VF, Rabna P, Gustafson P, Aaby P, Lisse IM, et al. Vitamin D as Supplementary Treatment for Tuberculosis. *Am J Respir Crit Care Med*. 2009; 179(9):843-50.
 26. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, et al. High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. *The Lancet*. 2011; 377(9761):242-50.
 27. Sinclair D, Abba K, Grobler L, Sudarsanam TD. Nutritional supplements for people being treated for active tuberculosis. *Cochrane Database Syst Rev*. 2011(11):CD006086.
 28. Sagert KB. International Agency for Research on Cancer (IARC). *Encyclopedia of Global Health: SAGE Publications*; 2008.
 29. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: A review (United States). *Cancer Causes & Control*. 2005; 16(2):83-95.
 30. Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJB, Norat T, Pischon T, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-

- control study. *BMJ*. 2010; 340(jan21 3):b5500-b.
31. Weinstein SJ, Purdue MP, Smith-Warner SA, Mondul AM, Black A, Ahn J, et al. Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *International Journal of Cancer*. 2014; 136(6):E654-E64.
 32. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D With or Without Calcium Supplementation for Prevention of Cancer and Fractures: An Updated Meta-analysis for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*. 2011; 155(12):827.
 33. Yin L, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. *Cancer Epidemiology*. 2009; 33(6):435-45.
 34. Gilbert R, Martin RM, Beynon R, Harris R, Savovic J, Zuccolo L, et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. *Cancer Causes & Control*. 2011; 22(3):319-40.
 35. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. *International Journal of Cancer*. 2011; 128(6):1414-24.
 36. Albanes D, Mondul AM, Yu K, Parisi D, Horst RL, Virtamo J, et al. Serum 25-Hydroxy Vitamin D and Prostate Cancer Risk in a Large Nested Case-Control Study. *Cancer Epidemiology Biomarkers & Prevention*. 2011; 20(9):1850-60.
 37. Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J, et al. A Prospective Nested Case-Control Study of Vitamin D Status and Pancreatic Cancer Risk in Male Smokers. *Cancer Research*. 2006; 66(20):10213-9.
 38. Helzlsouer KJ. Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. *American Journal of Epidemiology*. 2010; 172(1):4-9.
 39. Bauer SR, Hankinson SE, Bertone-Johnson ER, Ding EL. Plasma Vitamin D Levels, Menopause, and Risk of Breast Cancer. *Medicine*. 2013; 92(3):123-31.
 40. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. *Am J Clin Nutr*. 2007; 85(6):1586-91.
 41. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan MJ, et al. Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer. *New England Journal of Medicine*. 2006; 354(7):684-96.
 42. Caini S, Boniol M, Tosti G, Magi S, Medri M, Stanganelli I, et al. Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta-analysis. *Eur J Cancer*. 2014; 50(15):2649-58.
 43. Rostand SG. Ultraviolet Light May Contribute to Geographic and Racial Blood Pressure Differences. *Hypertension*. 1997; 30(2):150-6.
 44. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice. *Endocrine Reviews*. 2008; 29(6):726-76.
 45. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, Ethnicity, and Blood Pressure in the Third National Health and Nutrition Examination Survey. *American Journal of Hypertension*. 2007; 20(7):713-9.
 46. Burgaz A, Orsini N, Larsson SC, Wolk A. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. *Journal of Hypertension*. 2011; 29(4):636-45.
 47. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. *Journal of Hypertension*. 2009; 27(10):1948-54.
 48. Wu SH, Ho SC, Zhong L. Effects of Vitamin D Supplementation on Blood Pressure. *Southern Medical Journal*. 2010; 103(8):729-37.
 49. Pittas AG. Systematic Review: Vitamin D and Cardiometabolic Outcomes. *Annals of Internal Medicine*. 2010; 152(5):307.
 50. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, et al. Prevalence of Cardiovascular Risk Factors and the Serum Levels of 25-Hydroxyvitamin D in the United States. *Arch Intern Med*. 2007; 167(11):1159.

51. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D Deficiency and Risk of Cardiovascular Disease. *Circulation*. 2008; 117(4):503-11.
52. Wang L, Song Y, Manson JE, Pilz S, Marz W, Michaelsson K, et al. Circulating 25-Hydroxy-Vitamin D and Risk of Cardiovascular Disease: A Meta-Analysis of Prospective Studies. *Circulation: Cardiovascular Quality and Outcomes*. 2012; 5(6):819-29.
53. Sokol SI, Tsang P, Aggarwal V, Melamed ML, Srinivas VS. Vitamin D Status and Risk of Cardiovascular Events. *Cardiology in Review*. 2011; 19(4):192-201.
54. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. *Diabetic Medicine*. 2008; 25(3):320-5.
55. Bjorkman MP, Sorva AJ, Tilvis RS. Elevated serum parathyroid hormone predicts impaired survival prognosis in a general aged population. *European Journal of Endocrinology*. 2008; 158(5):749-53.
56. Grandi NC, Breitling LP, Brenner H. Vitamin D and cardiovascular disease: Systematic review and meta-analysis of prospective studies. *Preventive Medicine*. 2010; 51(3-4):228-33.
57. Pilz S, März W, Wellnitz B, Seelhorst U, Fahrleitner-Pammer A, Dimai HP, et al. Association of Vitamin D Deficiency with Heart Failure and Sudden Cardiac Death in a Large Cross-Sectional Study of Patients Referred for Coronary Angiography. *The Journal of Clinical Endocrinology & Metabolism*. 2008; 93(10):3927-35.
58. Melamed ML, Muntner P, Michos ED, Uribarri J, Weber C, Sharma J, et al. Serum 25-Hydroxyvitamin D Levels and the Prevalence of Peripheral Arterial Disease: Results from NHANES 2001 to 2004. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2008; 28(6):1179-85.
59. Pilz S, Dobnig H, Fischer JE, Wellnitz B, Seelhorst U, Boehm BO, et al. Low Vitamin D Levels Predict Stroke in Patients Referred to Coronary Angiography. *Stroke*. 2008; 39(9):2611-3.
60. Elamin MB, Abu Elnour NO, Elamin KB, Fatourehchi MM, Alkatib AA, Almandoz JP, et al. Vitamin D and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. *The Journal of Clinical Endocrinology & Metabolism*. 2011; 96(7):1931-42.
61. Takiishi T, Gysemans C, Bouillon R, Mathieu C. Vitamin D and Diabetes. *Endocrinology and Metabolism Clinics of North America*. 2010; 39(2):419-46.
62. Cooper JD, Smyth DJ, Walker NM, Stevens H, Burren OS, Wallace C, et al. Inherited Variation in Vitamin D Genes Is Associated With Predisposition to Autoimmune Disease Type 1 Diabetes. *Diabetes*. 2011; 60(5):1624-31.
63. Thorsen SU, Mortensen HB, Carstensen B, Fenger M, Thuesen BH, Husemoen LL, et al. No Difference in Vitamin D Levels Between Children Newly Diagnosed With Type 1 Diabetes and Their Healthy Siblings: A 13-Year Nationwide Danish Study. *Diabetes Care*. 2013; 36(9):e157-e8.
64. Joergensen C, Hovind P, Schmedes A, Parving HH, Rossing P. Vitamin D Levels, Microvascular Complications, and Mortality in Type 1 Diabetes. *Diabetes Care*. 2011; 34(5):1081-5.
65. Hyppönen E, Läärä E, Reunanen A, Järvelin M-R, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. *The Lancet*. 2001; 358(9292):1500-3.
66. Harris SS. Vitamin D and type 1 diabetes. *Am J Clin Nutr*. 2004; 79(5):889-90; author reply 90.
67. Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. *Archives of Disease in Childhood*. 2008; 93(6):512-7.
68. Minambres I, de Leiva A, Perez A. [Hypovitaminosis D and metabolic syndrome]. *Med Clin (Barc)*. 2014; 143(12):542-7.
69. Huang Y, Li X, Wang M, Ning H, A L, Li Y, et al. Lipoprotein lipase links vitamin D, insulin resistance, and type 2 diabetes: a cross-sectional epidemiological study. *Cardiovasc Diabetol*. 2013; 12(1):17.
70. Forouhi NG, Ye Z, Rickard AP, Khaw KT, Luben R, Langenberg C, et al. Circulating 25-hydroxyvitamin D concentration and the risk of type 2 diabetes: results from the

- European Prospective Investigation into Cancer (EPIC)-Norfolk cohort and updated meta-analysis of prospective studies. *Diabetologia*. 2012; 55(8):2173-82.
71. Song Y, Wang L, Pittas AG, Del Gobbo LC, Zhang C, Manson JE, et al. Blood 25-Hydroxy Vitamin D Levels and Incident Type 2 Diabetes: A meta-analysis of prospective studies. *Diabetes Care*. 2013; 36(5):1422-8.
 72. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The Role of Vitamin D and Calcium in Type 2 Diabetes. A Systematic Review and Meta-Analysis. *The Journal of Clinical Endocrinology & Metabolism*. 2007; 92(6):2017-29.
 73. de Boer IH, Tinker LF, Connelly S, Curb JD, Howard BV, Kestenbaum B, et al. Calcium Plus Vitamin D Supplementation and the Risk of Incident Diabetes in the Women's Health Initiative. *Diabetes Care*. 2008; 31(4):701-7.
 74. Pittas AG, Dawson-Hughes B, Li T, Van Dam RM, Willett WC, Manson JE, et al. Vitamin D and Calcium Intake in Relation to Type 2 Diabetes in Women. *Diabetes Care*. 2006; 29(3):650-6.
 75. George PS, Pearson ER, Witham MD. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. *Diabetic Medicine*. 2012; 29(8):e142-e50.
 76. Seida JC, Mitri J, Colmers IN, Majumdar SR, Davidson MB, Edwards AL, et al. Effect of Vitamin D 3 Supplementation on Improving Glucose Homeostasis and Preventing Diabetes: A Systematic Review and Meta-Analysis. *The Journal of Clinical Endocrinology & Metabolism*. 2014; 99(10):3551-60.
 77. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JPA. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. *BMJ*. 2014; 348(apr01 2):g2035-g.